Lupin shares in focus after $250 million U.S. facility plan; Citi retains buy call – News Air Insight

Shares of Lupin are likely to be in focus on Thursday after the Mumbai-based drugmaker announced plans to invest $250 million over five years to build a state-of-the-art manufacturing facility in Coral Springs, Florida. This move aims to bolster its U.S. respiratory business and diversify its supply chain.

Lupin said the new facility will produce more than 25 key respiratory medicines, including albuterol inhalers for children and U.S. service members. The investment, spread over five years, will cover research and development, infrastructure, and capital expenditure, the company said in a regulatory filing.

By strengthening domestic manufacturing and enhancing supply chain diversification, the company stated that the project will “enhance medicine security” and reinforce its position as a global leader in respiratory care. The site is also expected to create over 200 skilled, long-term jobs in Broward County by 2030.

“The expansion of Lupin’s footprint in Coral Springs is a core part of our growth strategy,” said Christoph Funke, Chief Technical Operations Officer at Lupin, adding that the new facility will build on the company’s existing Florida operations, which include its U.S. headquarters and Advanced Inhalation Research Centre.

Also read | 15 stocks to shop for this Diwali; SBI Securities eyes up to 25% upside. Check list

Anchoring U.S. respiratory production

Lupin said the Coral Springs facility will anchor its U.S. production of critical respiratory therapies, helping ensure “affordable, reliable access—from routine pediatric care to pandemic-scale demand.” The company has acquired over five acres of land for the project, which will house a 70,000-square-foot plant.In recognition of its investment and job creation plans, Lupin will receive tax credits and incentives from the state of Florida, it added.

Citi stays bullish

Brokerage Citi maintained its “Buy” rating on Lupin with a target price of Rs 2,260, saying the $250 million investment would strengthen the company’s U.S. respiratory portfolio and de-risk its complex inhaler pipeline.

Citi noted that the move “helps mitigate geopolitical and tariff risks,” while aligning with U.S. policy on domestic manufacturing.

Also read | Tata Steel shares are up 25% in 2025. Can the rally hold above Rs 175?

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)